...
首页> 外文期刊>Allergy, Asthma & Clinical Immunology >Lymphocyte Kv1.3-channels in the pathogenesis of chronic obstructive pulmonary disease: novel therapeutic implications of targeting the channels by commonly used drugs
【24h】

Lymphocyte Kv1.3-channels in the pathogenesis of chronic obstructive pulmonary disease: novel therapeutic implications of targeting the channels by commonly used drugs

机译:慢性阻塞性肺疾病发病机制中的淋巴细胞Kv1.3-通道:通过常用药物靶向通道的新治疗意义

获取原文
           

摘要

In patients with chronic obstructive pulmonary disease (COPD), over-activated T-lymphocytes produce pro-inflammatory cytokines and proliferate in situ in the lower airways and pulmonary parenchyma, contributing substantially to the pathogenesis of the disease. Despite our understanding of the molecular mechanisms by which lymphocytes are activated, we know little about the physiological mechanisms. T-lymphocytes predominantly express delayed rectifier K+-channels (Kv1.3) in their plasma membranes and these channels play crucial roles in inducing the lymphocyte activation and proliferation. In the pathogenesis of chronic inflammatory diseases, such as chronic kidney disease (CKD) or inflammatory bowel disease (IBD), these channels, which are overexpressed in proliferating lymphocytes within the inflamed organs, are responsible for the progression of the diseases. Since the over-activation of cellular immunity is also mainly involved in the pathogenesis of COPD, this disease could share similar pathophysiological features as those of CKD or IBD. From a literature review including ours, it is highly likely that the Kv1.3-channels are overexpressed or over-activated in T-lymphocytes isolated from patients with COPD, and that the overexpression of the channels would contribute to the development or progression of COPD. The involvement of the channels leads to novel therapeutic implications of potentially useful Kv1.3-channel inhibitors, such as calcium channel blockers, macrolide antibiotics, HMG-CoA reductase inhibitors and nonsteroidal anti-inflammatory drugs, in the treatment of COPD.
机译:在患有慢性阻塞性肺疾病(COPD)的患者中,过度活化的T淋巴细胞会产生促炎性细胞因子,并在下气道和肺实质中原位增殖,从而大大促进了该疾病的发病机理。尽管我们了解激活淋巴细胞的分子机制,但对生理机制知之甚少。 T淋巴细胞主要在其质膜上表达延迟的整流子K + 通道(Kv1.3),这些通道在诱导淋巴细胞活化和增殖中起关键作用。在诸如慢性肾脏病(CKD)或炎性肠病(IBD)的慢性炎性疾病的发病机理中,这些通道在发炎器官内的增殖淋巴细胞中过表达,是导致疾病进展的原因。由于细胞免疫的过度激活也主要参与了COPD的发病机制,因此该疾病可能具有与CKD或IBD相似的病理生理特征。从包括我们在内的文献综述中,很可能在从COPD患者分离的T淋巴细胞中Kv1.3通道过度表达或过度活化,并且通道的过度表达将有助于COPD的发生或发展。通道的参与导致潜在有用的Kv1.3通道抑制剂(如钙通道阻滞剂,大环内酯类抗生素,HMG-CoA还原酶抑制剂和非甾体类抗炎药)在治疗COPD中具有新的治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号